Navidea highlights research on melanoma, oral cancer

By staff writers

August 2, 2022 -- Radiopharmaceutical developer Navidea Biopharmaceuticals is directing attention to new research from Australia on the use of its technetium-99m (Tc-99m) tilmanocept radiopharmaceutical in patients with melanoma or oral cancer.

Researchers from the University of Sydney prospectively assessed Tc-99m tilmanocept (also known as Lymphoseek) as a biomarker for lymphatic mapping and sentinel lymph node biopsy in 35 patients. They found that lymphoscintigraphy with Tc-99m tilmanocept identified at least one sentinel lymph node in all patients and enabled a 100% intraoperative retrieval rate of these lymph nodes in all patients.

What's more, imaging with Lymphoseek demonstrated 100% tissue specificity; lymph nodal tissue was confirmed histologically and there were no false positives, according to Navidea.

The study was published July 18 in the ANZ Journal of Surgery.

Copyright © 2022
Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking